A5040845933- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Protein Degradation and Inhibitors
- Parathyroid Disorders and Treatments
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- COVID-19 and healthcare impacts
- Histone Deacetylase Inhibitors Research
- HIV/AIDS drug development and treatment
- Cardiac Structural Anomalies and Repair
- Hematopoietic Stem Cell Transplantation
- Cancer Mechanisms and Therapy
- Intramuscular injections and effects
- Atrial Fibrillation Management and Outcomes
- Palliative Care and End-of-Life Issues
- Heparin-Induced Thrombocytopenia and Thrombosis
- CAR-T cell therapy research
- BRCA gene mutations in cancer
UNSW Sydney
2020-2025
The Kinghorn Cancer Centre
2021-2025
St Vincent's Hospital
2020-2025
St Vincent's Clinic
2021-2025
Garvan Institute of Medical Research
2023-2024
St Vincent's Hospital Sydney
2020-2024
St. Vincent's Birmingham
2023
St. Vincent's Hospital
2023
Westmead Hospital
2017-2022
The University of Sydney
2011-2021
Abstract Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib. We aimed to analyze the real-world prevalence of versus twice-weekly bortezomib in newly diagnosed MM. analyzed 2497 US patients aged 18–70 years treated commercial first-line using nationwide Flatiron Health electronic health record-derived data,...
Virus-specific T-cells (VSTs) from third-party donors mediate short- and long-term antiviral effects in allogeneic hematopoietic stem cell transplant (HSCT) recipients with relapsed or refractory viral infections. We investigated early administration of VSTs, together therapy patients requiring treatment for first cytomegalovirus (CMV) Epstein-Barr virus (EBV) infection. Thirty HSCT were treated 1 to 4 VST infusions (2 × 107 cells/m2; CMV n=27, EBV n=3) at a median days after initiation...
Abstract The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known cause disproportionately severe disease in cancer, and lymphoma, myeloma chronic lymphocytic leukaemia are likely be at particular risk related COVID‐19. This statement has been developed by consensus among authors from Australia New Zealand. We aim provide supportive guidance clinicians making individual patient decisions during pandemic, periods that...
Background: Cancer treatment can significantly reduce reproductive potential in female patients. This study sought to explore the incidence of fertility counseling women childbearing before, during, and after anticancer therapies. Methods: We conducted a retrospective medical record review at major Australian cancer center premenopausal females aged 18 49 years diagnosed with between 2017 2020. Results: A total 143 patients met inclusion criteria. Of these patients, only 12.6% had health...
Abstract Cardiac amyloidosis is a progressive infiltrative disease and an important cause of atrial arrhythmias, stroke heart failure. Abnormal amyloid fibril deposition throughout the leads to host clinical manifestations complications. Although abnormalities are typically regarded as consequence ventricular diastolic dysfunction or there emerging evidence that primary defects structure function may be present. An cardiomyopathy sign early cardiac disease, unrecognised independent marker...
Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, although many patients are cured with conventional multimodal therapy, those recurrent or metastatic disease have poor prognosis. Genomic instability programmed cell death ligand-1 (PD-L1) expression been identified in EWS, providing rationale for treatment agents that block the death-1 (PD-1) receptor. In this report, we describe heavily pre-treated patient EWS who achieved clinical radiological remission PD-1 blockade. To...
Alemtuzumab is a highly efficacious therapy used in the treatment of multiple sclerosis (MS), but uncoupling T and B cell repopulation during immune reconstitution associates with an increasing range secondary cell-mediated autoimmune complications. A 34-year-old woman developed Graves' disease 11 months following initial course alemtuzumab for MS. Nine second alemtuzumab, patient presented spontaneous intramuscular subcutaneous haemorrhage due to development inhibitory autoantibody...
Australia and New Zealand have achieved excellent community control of COVID‐19 infection. In light the imminent vaccination roll out in both countries, representatives from Haematology Society infectious diseases specialists collaborated on this consensus position statement regarding patients with haematological disorders. It is our recommendation that malignancies, some benign disorders, should expedited access to high‐efficacy vaccines, given these are at high risk morbidity mortality...
Abstract: Anticoagulant therapy is prescribed for many clinical indications, including treatment and prevention of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) pulmonary embolism (PE), well stroke prophylaxis in atrial fibrillation (AF) to reduce the risk prosthetic heart valve thromboembolism. In this narrative review, we briefly outline anticoagulants available Australia, their relative strengths weaknesses, ever-changing local landscape with regards anticoagulation therapy.
Background: Belantamab Mafodotin (Belamaf), a first in class anti- B-cell maturation antigen (BCMA) antibody-drug conjugate is efficacious patients with triple-class exposed/refractory multiple myeloma (RRMM). Combining Belamaf (B) carfilzomib and dexamethasone (Kd) potentially synergistic through direct myeloma-cell kill immune response against myeloma. Aims: To characterize the safety, tolerability, preliminary efficacy of BelaMaf combination early relapsed MM. Methods: BelaCarD an...
Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple consists multi-line chemotherapy with or without autologous stem transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients clinicians long-term prognostic information nor policymakers full body evidence needed perform economic evaluation new therapies make reimbursement decisions....